BioCentury | Feb 5, 2021
Finance

Immunocore rises, Vor doubles in value as busy week concludes for IPOs

...in its history before raising $258.3 million in its IPO at a $1.1 billion postmoney valuation.Vor Biopharma Inc....
...for cancer.As a group, the 10 companies raised nearly $1.9 billion. Paul Bonanos Immunocore Holdings Ltd. Sana Biotechnology Inc. Vor Biopharma Inc. Pharvaris...
BioCentury | Feb 2, 2021
Finance

Sana among 10 biotechs set to flood market for IPOs

...biotechs due to trade on Friday: Immunocore Ltd., Sensei Biotherapeutics Inc., Terns Pharmaceuticals Inc. and Vor Biopharma...
BioCentury | Jan 20, 2021
Finance

IPO queue upswelling: Data Byte

...Friday, ready to test investors’ appetite anew following a record-setting year for IPOs. At $150 million, Vor Biopharma Inc....
...listing on NASDAQ. Winnie Pong Lucira Health Inc. LumiraDx Ltd. Angion Biomedica Corp. Immunocore Holdings Ltd. Pharvaris N.V. Terns Pharmaceuticals Inc. Bolt Biotherapeutics Inc. Vor Biopharma Inc. Decipher...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...Inc.’s SAB and serves as a Columbia University hematologist and oncologist. He is also a co-founder of Vor Biopharma...
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...of Passage Bio Inc. (NASDAQ:PASG), succeeds Pierluigi Paracchi, who will remain Genenta’s CEO. Stem cell company Vor Biopharma Inc....
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...the company announced a non-exclusive preclinical partnership with Vor Biopharma Inc....
...and Jillian Banfield University collaborators: N/ACorporate partners: Vor Biopharma...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

...at Columbia University, a prolific author of non-fiction articles and books and scientific co-founder of Vor Biopharma Inc....
...within Indian hospitals to manufacturer cell therapies and to train staff to administer them. Steve Usdin 5AM Ventures Vor Biopharma Inc. Immuneel...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Quiroz as EVP and CMO, a new position. He was CMO of Solid Biosciences Inc. (NASDAQ:SLDB).Vor Biopharma Inc....
...the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics Inc. Immunovia AB Apic Bio Inc. Vor Biopharma Inc. Organogenesis...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...a $150 million series B round in June (see “Crossovers Pile into New Rounds” ). Vor Biopharma Inc....
...binding Ig like lectin 15 Robin Sawka, BioCentury Staff Waters Corp. Vertex Pharmaceuticals Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn...
BioCentury | Jul 8, 2020
Finance

Crossovers pile into $110M series B as Vor heads into the clinic

...PureTech Health plc (LSE:PRTC). CEO Robert Ang and 5AM's Kush Parmar declined to discuss whether Vor Biopharma Inc.'s...
...develop its own targeted cancer therapies internally, said Ang. Targets CD33 (SIGLEC3) Sandi Wong, Assistant Editor 5AM Ventures Vor Biopharma Inc. PureTech...
Items per page:
1 - 10 of 24
BioCentury | Feb 5, 2021
Finance

Immunocore rises, Vor doubles in value as busy week concludes for IPOs

...in its history before raising $258.3 million in its IPO at a $1.1 billion postmoney valuation.Vor Biopharma Inc....
...for cancer.As a group, the 10 companies raised nearly $1.9 billion. Paul Bonanos Immunocore Holdings Ltd. Sana Biotechnology Inc. Vor Biopharma Inc. Pharvaris...
BioCentury | Feb 2, 2021
Finance

Sana among 10 biotechs set to flood market for IPOs

...biotechs due to trade on Friday: Immunocore Ltd., Sensei Biotherapeutics Inc., Terns Pharmaceuticals Inc. and Vor Biopharma...
BioCentury | Jan 20, 2021
Finance

IPO queue upswelling: Data Byte

...Friday, ready to test investors’ appetite anew following a record-setting year for IPOs. At $150 million, Vor Biopharma Inc....
...listing on NASDAQ. Winnie Pong Lucira Health Inc. LumiraDx Ltd. Angion Biomedica Corp. Immunocore Holdings Ltd. Pharvaris N.V. Terns Pharmaceuticals Inc. Bolt Biotherapeutics Inc. Vor Biopharma Inc. Decipher...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...Inc.’s SAB and serves as a Columbia University hematologist and oncologist. He is also a co-founder of Vor Biopharma...
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...of Passage Bio Inc. (NASDAQ:PASG), succeeds Pierluigi Paracchi, who will remain Genenta’s CEO. Stem cell company Vor Biopharma Inc....
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...the company announced a non-exclusive preclinical partnership with Vor Biopharma Inc....
...and Jillian Banfield University collaborators: N/ACorporate partners: Vor Biopharma...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

...at Columbia University, a prolific author of non-fiction articles and books and scientific co-founder of Vor Biopharma Inc....
...within Indian hospitals to manufacturer cell therapies and to train staff to administer them. Steve Usdin 5AM Ventures Vor Biopharma Inc. Immuneel...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Quiroz as EVP and CMO, a new position. He was CMO of Solid Biosciences Inc. (NASDAQ:SLDB).Vor Biopharma Inc....
...the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics Inc. Immunovia AB Apic Bio Inc. Vor Biopharma Inc. Organogenesis...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...a $150 million series B round in June (see “Crossovers Pile into New Rounds” ). Vor Biopharma Inc....
...binding Ig like lectin 15 Robin Sawka, BioCentury Staff Waters Corp. Vertex Pharmaceuticals Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn...
BioCentury | Jul 8, 2020
Finance

Crossovers pile into $110M series B as Vor heads into the clinic

...PureTech Health plc (LSE:PRTC). CEO Robert Ang and 5AM's Kush Parmar declined to discuss whether Vor Biopharma Inc.'s...
...develop its own targeted cancer therapies internally, said Ang. Targets CD33 (SIGLEC3) Sandi Wong, Assistant Editor 5AM Ventures Vor Biopharma Inc. PureTech...
Items per page:
1 - 10 of 24